Web Development
Full-Stack Builds
Next.js, Laravel, Shopify, WordPress. From architecture to launch.
Learn moreDhima Consulting
We build software that mimics your process — instead of forcing your process to mimic the software. Custom systems shaped around how your business actually runs, plus long-form writing on tech, AI, and what actually works.
How We Work
Most off-the-shelf software forces you to bend your business to fit the tool — re-learning your own workflow to match someone else's idea of how it should go. We do the opposite. We start with how your business actually runs, then build software that mirrors that process step for step.
That's where we focus: operational software that makes a business run — CRMs, dashboards, logistics, and the process-heavy workflows that move the day forward. The software adapts to you, so your team keeps working the way it already knows how — just faster, and without the busywork.
We own the whole stack, end to end — the code, the infrastructure, and the accountability. Simple, reliable, measurable. If it doesn't move the needle, it doesn't ship.
Web Development
Next.js, Laravel, Shopify, WordPress. From architecture to launch.
Learn moreSEO & Strategy
Technical SEO, keyword strategy, and content engines that compound.
Learn moreInfrastructure
cPanel fleet management, server hardening, CI/CD pipelines.
Learn moreAutomation & AI
Claude API, MCP tools, agentic workflows. Automate the repetitive.
Learn moreLatest Thoughts
October 5, 2026
A flydubai co-pilot allegedly attacked his captain with a crash axe on a Dubai–Tel Aviv flight; a wounded captain, a plumber and two spare pilots saved 174 people. The near miss exposes the threat post-9/11 cockpit security never addressed: the person already inside.
September 14, 2026
Using tomorrow’s tools can reveal tomorrow’s needs. Turning that glimpse into a business requires evidence that someone else wants the result.
September 8, 2026
An AI-designed lung drug made six independent aging clocks run backward. But the study was a retrospective read of banked blood from 42 terminally ill patients, and the Phase III trial now running has no aging endpoint at all. What the rentosertib result actually shows.